Johnson & Johnson-backed Rapport Therapeutics secures USD 154 million in US IPO
London: Rapport Therapeutics,, backed by the venture capital arm of Johnson & Johnson has said that the Company has secured $154 million in its initial public offering (IPO) in the United States at a valuation of approximately $601.4 million.
The company intends to sell 8 million shares at $17 each, priced at the midpoint of its anticipated price range of $16-$18 apiece.
Rapport develops small molecule medicines for patients suffering from central nervous system disorders.
The Boston, Massachusetts-based company was formed in February 2022 with founding support from Third Rock Ventures and Johnson & Johnson Innovation-JJDC.
Initially named Precision Neuroscience NewCo, Rapport has said that it plans to use a portion of the IPO proceeds to advance the clinical development of its lead product candidate, RAP-219, for the treatment of focal epilepsy.
The IPO shows that the U.S. IPO market has made a strong comeback after two dismal years.
Companies have raised more than $15 billion this year via IPOs on U.S. exchanges, according to Dealogic, up sharply from about $9.1 billion at this point last year, the data shows.
Goldman Sachs, Jefferies, TD Cowen and Stifel are the underwriters for the offering.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd